Combotope Therapeutics

Combotope Therapeutics aims to become the leading provider of truly tumor-specific monoclonal antibody (mAb)-based therapies, addressing the needs of all cancer patients across various cancer types without compromising healthy cells. Founded in 2023, Combotope Therapeutics is the creator of the proprietary mAb discovery platform, Integrated Design Antibody Library (iDEAL), which is designed to target abnormally glycosylated proteins on cancer cells while sparing healthy cells that express the same but naturally glycosylated proteins. The identified scFv sequences exhibit high affinity, making them suitable for integration into various therapeutic modalities to achieve effective cancer treatment.